Breaking Finance News

Galectin Therapeutics Inc (NASDAQ:GALT) target price raised to $1.50, issued a report today by HC Wainwright

Boasting a price of $1.40, Galectin Therapeutics Inc (NASDAQ:GALT) traded -12.86% lower on the day. With the last stock price close down -23.95% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Galectin Therapeutics Inc has recorded a 50-day average of $1.88 and a two hundred day average of $1.60. Volume of trade was up over the average, with 2,549,913 shares of GALT changing hands over the typical 584,859

Galectin Therapeutics Inc (NASDAQ:GALT) had its price target upped to $1.50 by HC Wainwright in a report issued 9/29/2016. The updated stock price target implies a possible upside of 0.07% from the company's most recent stock price close.

Performance Chart

Galectin Therapeutics Inc (NASDAQ:GALT)

With a total market value of $0, Galectin Therapeutics Inc has with a one year low of $1.08 and a one year high of $3.25 .

A total of 3 brokerages have released a report on Galectin Therapeutics Inc. One brokerage rating the company a strong buy, two brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $8.33.

General Company Details For Galectin Therapeutics Inc (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *